Hearing Loss May Leave Clues in DNA Before First Symptoms

A study involving thousands of participants has shown that detailed hearing tests can reveal genetic clues linked to hearing loss, clues that often go unnoticed during conventional medical diagnoses. While it is not yet possible to predict with certainty who will develop hearing loss, this discovery could contribute to more accurate risk assessments in the future.
Hearing loss may have genetic roots that exist long before the first symptoms appear. Identifying these influences could help in recognizing individuals with a higher predisposition to the condition. To investigate this, researchers compared two methods of studying hearing loss: diagnoses recorded in medical charts versus measurements obtained through specific hearing tests.
The scientists analyzed genetic data and health information from thousands of participants. In the first approach, they compared individuals with and without a formal diagnosis of sensorineural hearing loss, a type of hearing loss caused by changes in the inner ear or the neural structures that transmit sound to the brain. In the second approach, they used audiograms, tests that measure the ability to hear sounds at various frequencies.

The researchers calculated the average of the quietest sounds each person could hear across three frequencies, focusing on the ear with better hearing. This allowed them to identify subtle differences among the participants, rather than simply categorizing them as having or not having hearing loss.
Next, the researchers examined the DNA in search of genetic variations associated with hearing ability. To do this, they used a method that compares hundreds of thousands or millions of points within the genetic material of individuals with different characteristics.
They also estimated heritability, a measure indicating the extent to which the observed differences between individuals can be explained by the genetic variations analyzed. This measure does not represent the percentage of an individual's hearing loss that is caused by their genes.
The results showed that the assessment based on audiograms identified five genetic regions associated with hearing, linked to four candidate genes. In contrast, the analysis based on medical diagnoses did not uncover genetic associations strong enough to meet the established statistical criteria.

The estimated heritability was also higher when using hearing tests, approximately 11.8%, compared to 2.9% when using diagnostic codes. This suggests that measuring hearing ability directly may reveal genetic influences that medical records fail to capture.
Finally, the scientists tested their findings on another group of participants from the U.S.-based All of Us program. They combined the effects of various genetic variants into a calculation known as a polygenic risk score, which is used to estimate genetic predispositions.
Scores based on audiograms showed an association with self-reported deafness among participants, whereas those derived from medical diagnoses did not. Although promising, this approach cannot yet predict with certainty who will develop hearing loss or when it might occur.
Furthermore, since the study relied on data from individuals of European genetic ancestry, research involving more diverse populations is necessary before the findings can be applied in a clinical setting.
READ MORE:
Precision Phenotyping With Audiometric Data and Gene Discovery for Sensorineural Hearing Loss
Andrea J. DeFreese, Tanguy Rubat du Mérac, Quanhu Sheng, Srishti Nayak, and Taha A. Jan
JAMA Otolaryngology, Head & Neck Surgery. October 8, 2026
DOI: 10.1001/jamaoto.2026.3089
Abstract:
Importance The genetic architecture underlying hearing sensitivity as a quantitative trait is critical for advancing precision medicine in hearing health. Despite extensive genome-wide association study (GWAS) efforts, few strong genetic drivers have been identified.
Objective To compare the sensitivity for detecting genetic variants associated with sensorineural hearing loss (SNHL) using precision phenotyping with pure-tone averages (PTAs) with common phenotyping using diagnostic coding approaches.
Design, Setting, and Participants In this genetic association study, 2 separate GWASs were conducted using different phenotyping approaches for SNHL: (1) diagnostic code control and (2) precision phenotyping with PTA data. Whole-genome sequencing data from a population with European genetic ancestry collected at a single tertiary center biobank was used. For the control GWAS based on diagnostic codes, case and control participants were defined using primarily International Classification of Diseases, Ninth Revision (ICD-9) and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) diagnosis and procedure codes related to SNHL hearing loss. For the precision phenotyping GWAS, hearing status was defined as a continuous variable, using the standard 3-frequency PTA of the better hearing ear from the audiogram. Data analysis was conducted from August 2025 to April 2026.
Main Outcomes and Measures GWAS summary statistics were used to calculate estimates of single-nucleotide variant (SNV)–based heritability for PTA and ICD phenotypes; to map the genetic risk loci to candidate genes using functional annotation; to evaluate genetic correlations with existing GWASs; and to calculate polygenic risk scores for testing in an independent cohort from the National Institutes of Health’s All of Us Research Program.
Results Overall, 10 164 case participants (mean [SD] age, 63.9 [21.3] years; 5118 [50.4%] female) and 51 305 control participants (mean [SD] age, 51.1 [21.0] years; 28 784 [56.1%] female) were included in the first GWAS; 16 057 participants with PTA (mean [SD] age, 55.5 [21.8] years; 9147 [57.0%] female) were included in the second GWAS. PTA-based GWAS identified 3 genome-wide significant loci mapped to 4 genes: EML6, SPTBN1, ARHGEF28, and EYA4 (SNV-based heritability estimate [h2] = 11.78%; SE = 2.84%). ICD-based GWAS identified no significant loci (h2 = 2.90%; SE = 0.77%). Genome-wide correlations between the PTA-based GWAS and 3 hearing-related ability traits were found (eg, PTA-based GWAS and hearing aid use: r = 0.985; SE = 0.163; P = 1.56 × 10−9). In the All of Us cohort, PTA-derived polygenic risk scores were significantly associated with self-reported deafness (odds ratio [OR], 1.09; 95% CI, 1.07-1.12), whereas ICD-derived scores were not (OR, 1.00; 95% CI, 0.97-1.02).
Conclusions and Relevance In this genetic association study, precision phenotyping using audiometric PTAs improved genetic discovery for SNHL compared with diagnostic code–based approaches. Higher heritability estimates, identification of genome-wide significant loci, and stronger polygenic risk estimation indicate that quantitative hearing measures better capture genetic architecture, supporting precision medicine in hearing health.



Comments